keyword
MENU ▼
Read by QxMD icon Read
search

HIV, Hepatitis c

keyword
https://www.readbyqxmd.com/read/29774442/integrated-models-of-care-for-individuals-with-opioid-use-disorder-how-do-we-prevent-hiv-and-hcv
#1
REVIEW
Katherine M Rich, Joshua Bia, Frederick L Altice, Judith Feinberg
PURPOSE OF REVIEW: To describe models of integrated and co-located care for opioid use disorder (OUD), hepatitis C (HCV), and HIV. RECENT FINDINGS: The design and scale-up of multidisciplinary care models that engage, retain, and treat individuals with HIV, HCV, and OUD are critical to preventing continued spread of HIV and HCV. We identified 17 models within primary care (N = 3), HIV specialty care (N = 5), opioid treatment programs (N = 6), transitional clinics (N = 2), and community-based harm reduction programs (N = 1), as well as two emerging models...
May 17, 2018: Current HIV/AIDS Reports
https://www.readbyqxmd.com/read/29771789/raltegravir-1200-mg-once-daily-vs-400-mg-twice-daily-with-emtricitabine-and-tenofovir-disoproxil-fumarate-for-previously-untreated-hiv-1-infection-week-96-results-from-oncemrk-a-randomized-double-blind-non-inferiority-trial
#2
Pedro Cahn, Paul E Sax, Kathleen Squires, Jean-Michel Molina, Winai Ratanasuwan, Mohammed Rassool, Mark Bloch, Xia Xu, Yan Zhou, Brenda Homony, Deborah Hepler, Hedy Teppler, George J Hanna, Bach-Yen Nguyen, Wayne Greaves
BACKGROUND: Raltegravir 1200mg (2x600mg tablets) once daily (QD) demonstrated non-inferior efficacy and similar safety to raltegravir 400mg BID at Week 48 of the ONCEMRK trial. Here we report the Week 96 results from this study. METHODS: ONCEMRK is a phase 3, multicenter, double-blind, non-inferiority trial comparing raltegravir 1200mg QD to raltegravir 400mg BID in treatment-naïve HIV-1-infected adults. Participants were assigned (2:1) to raltegravir 2x600mg QD or 400mg BID, both with emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) for 96 weeks...
May 3, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29771680/factors-associated-with-time-between-using-a-drug-and-injection-initiation-among-people-who-inject-drugs-in-kermanshah-iran
#3
Mehdi Noroozi, Mohammad Hassan Farhadi, Bahram Armoon, Ali Farhoudian, Zahra Jorjoran Shushtari, Asaad Sharhani, Salah Eddin Karimi, Mohammad Sayadnasiri, Omid Rezaei, Hesam Ghiasvand
Background The transition from non-injection to injection drug use dramatically increases the risk of transmitting HIV and other blood borne infections including hepatitis B virus (HBV) and hepatitis C virus (HCV). The aim of this study was to explore factors associated with the transition from first illicit drug use to first injection among drug users. Methods Using snowball sampling and convenience sampling through needle and syringe programmes (NSPs), we recruited 500 people who inject drugs (PWID) in Kermanshah, between September and December 2014...
May 17, 2018: International Journal of Adolescent Medicine and Health
https://www.readbyqxmd.com/read/29770077/outbreaks-in-the-age-of-syndemics-new-insights-for-improving-indigenous-health
#4
A Andermann
Conventional approaches for the prevention and control of communicable diseases within Indigenous contexts may benefit from new insights arising from the growing interest in syndemics. Syndemics is a term used to describe a conceptual framework for understanding diseases or health conditions, and how these are exacerbated by the social, economic, environmental and political milieu in which a population is immersed. The use of conventional approaches for outbreak prevention and control remains the bedrock of intervention in the field of communicable diseases; yet on their own, these strategies are not always successful, especially within contexts of marginalization and disadvantage...
June 1, 2017: Canada Communicable Disease Report, Relevé des Maladies Transmissibles Au Canada
https://www.readbyqxmd.com/read/29769038/impact-of-new-daa-therapy-on-real-clinical-practice-a-multicenter-region-wide-cohort-study
#5
Simone Lanini, Paola Scognamiglio, Alessandra Mecozzi, Lorella Lombardozzi, Vincenzo Vullo, Mario Angelico, Antonio Gasbarrini, Gloria Taliani, Adolfo Francesco Attili, Carlo Federico Perno, Adriano De Santis, Vincenzo Puro, Fabio Cerqua, Gianpiero D'Offizi, Adriano Pellicelli, Orlando Armignacco, Francesco Saverio Mennini, Massimo Siciliano, Enrico Girardi, Vincenzo Panella, Giuseppe Ippolito
BACKGROUND: Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs. METHODS: The study was designed as a multicenter cohort: a) to assess the evolution of treatment during the first 24 months of the activity of the Clinical Network; b) to report overall efficacy of treatments; c) to analyze potential factors associated with lack of virological response at 12 weeks after therapy (SVR12); d) to evaluate the variation of ALT at baseline and 12 weeks after therapy in those who achieved SVR12 in comparison to those who did not...
May 16, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29766745/incidence-of-acute-kidney-injury-in-patients-co-infected-with-hiv-and-hepatitis-c-virus-receiving-tenofovir-disoproxil-fumarate-and-ledipasvir-sofosbuvir-in-a-real-world-urban-ryan-white-clinic
#6
Jessica L Michal, Saira Rab, Manish Patel, Alison Kyle, Lesley Miller, Kirk A Easley, Aley Kalapila
Background Ledipasvir/sofosbuvir (LDV/SOF), an antiviral treatment for hepatitis C virus (HCV), and tenofovir disoproxil fumarate (TDF), an antiretroviral for treating human immunodeficiency virus (HIV), may be co-administered in patients co-infected with these viruses. A drug interaction between LDV and TDF could increase TDF-associated nephrotoxicity rates; however, there is minimal clinical evidence describing acute kidney injury (AKI) rates in this population. Setting This study was conducted at a Ryan White-funded facility in Atlanta, Georgia, that cares for over 5,000 patients with AIDS...
May 16, 2018: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/29766018/usefulness-of-simultaneous-screening-for-hiv-and-hepatitis-c-specific-antibodies-and-hepatitis-b-surface-antigen-by-capillary-based-multiplex-immunochromatographic-rapid-test-to-strengthen-prevention-strategies-and-linkage-to-care-in-childbearing-aged-women
#7
Ralph-Sydney Mboumba Bouassa, Zita Aleyo Nodjikouambaye, Damtheou Sadjoli, Ali Mahamat Moussa, Chatte Adawaye, Donato Koyalta, Laurent Bélec
Childbearing-aged women (n = 266) attending a gynecological clinic in Chad were subjected to multiplex immunochromatographic rapid test for HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV). Ten (3.7%) and 8 (3.0%) were seropositive for HIV and HCV, respectively, and 20 (7.5%) for HBV surface antigen, allowing diagnosis of chronic viral infections in 1 of 7 (14.3%) women.
May 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/29765442/hepatitis-c-coinfection-adversely-affects-the-life-expectancy-of-people-living-with-hiv-in-northwestern-poland
#8
Magdalena Leszczyszyn-Pynka, Piotr Ciejak, Katarzyna Maciejewska, Magdalena Witak-Jędra, Malwina Karasińska-Cieślak, Ewa Karpińska, Marta Wawrzynowicz-Syczewska, Miłosz Parczewski
Introduction: Hepatitis C (HCV) infection adversely affects survival among people living with HIV, increasing mortality risk due to liver-related causes. In Poland HCV is found among ~30% of HIV infected individuals, with only a small percentage successfully treated for this coinfection. This study aimed to analyze the HCV-associated influence on the life expectancy among HIV/HCV coinfected patients from northwestern Poland. Material and methods: Longitudinal data of 701 (368 HIV monoinfected and 368 HIV/HCV coinfected) patients were investigated to assess the life expectancy and survival after HIV diagnosis...
April 2018: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/29765256/grazoprevir-elbasvir-for-the-treatment-of-adults-with-chronic-hepatitis-c-a-short-review-on-the-clinical-evidence-and-place-in-therapy
#9
REVIEW
Nimisha Sulejmani, Syed-Mohammed Jafri
Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide. Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and is an all-oral once daily treatment option for HCV infection...
2018: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/29760420/engineering-modular-intracellular-protein-sensor-actuator-devices
#10
Velia Siciliano, Breanna DiAndreth, Blandine Monel, Jacob Beal, Jin Huh, Kiera L Clayton, Liliana Wroblewska, AnneMarie McKeon, Bruce D Walker, Ron Weiss
Understanding and reshaping cellular behaviors with synthetic gene networks requires the ability to sense and respond to changes in the intracellular environment. Intracellular proteins are involved in almost all cellular processes, and thus can provide important information about changes in cellular conditions such as infections, mutations, or disease states. Here we report the design of a modular platform for intrabody-based protein sensing-actuation devices with transcriptional output triggered by detection of intracellular proteins in mammalian cells...
May 14, 2018: Nature Communications
https://www.readbyqxmd.com/read/29759421/prevalence-and-distribution-of-hepatitis-c-virus-genotypes-in-galicia-during-the-period-2000-2015
#11
Daniel Navarro-de la Cruz, Sonia Pérez-Castro, Matilde Trigo-Daporta, Antonio Aguilera-Guirao
INTRODUCTION: We present the largest study conducted in Galicia on the prevalence and distribution of HCV genotypes/subtypes. METHODS: Retrospective study collecting the total number of patients chronically infected by HCV between 2000.01.01 to 2015.12.31 in 3of the main health areas: Santiago, Pontevedra and Vigo. RESULTS: We collected a total of 4469 patients. The median age was 50 years (IQR 57-45), 72,3% were men, 0,4% were coinfected with another genotype, 20,6% were coinfected with HIV and 35...
May 11, 2018: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/29758235/innovation-and-trends-in-the-development-and-approval-of-antiviral-medicines-1987-2017-and-beyond
#12
REVIEW
Shuvam Chaudhuri, Julian A Symons, Jerome Deval
2017 marked the 30th anniversary of the approval of zidovudine (AZT) as the first HIV/AIDS therapy. Since then, more than eighty antiviral drugs have received FDA approval, half of which treat HIV infection. Here, we provide a retrospective analysis of approved antiviral drugs, including therapeutics against other major chronic infections such as hepatitis B and C, and herpes viruses, over the last thirty years. During this time, only a few drugs were approved to treat acute viral infections, mainly influenza...
May 11, 2018: Antiviral Research
https://www.readbyqxmd.com/read/29755758/autoantibodies-in-chronic-hepatitis-c-virus-infection-impact-on-clinical-outcomes-and-extrahepatic-manifestations
#13
Andrew J Gilman, An K Le, Changqing Zhao, Joseph Hoang, Lee A Yasukawa, Susan C Weber, John M Vierling, Mindie H Nguyen
Goals: To examine the role that autoantibodies (auto-abs) play in chronic hepatitis C virus (HCV) regarding demographics, presence of extrahepatic manifestations and long-term outcomes in a large US cohort. Background: Auto-abs have been reported to be prevalent in patients with chronic HCV infection, but data on the natural history of these patients are limited. Study: The study included 1556 consecutive patients with HCV without concurrent HIV and/or HBV who had testing for antinuclear antibody (ANA), antimitochondrial antibody (AMA), antismooth muscle antibody (ASMA) and/or antiliver kidney microsomal antibody (LKM)...
2018: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/29755578/a-systematic-review-and-meta-analysis-of-gender-difference-in-epidemiology-of-hiv-hepatitis-b-and-hepatitis-c-infections-in-people-with-severe-mental-illness
#14
REVIEW
Getinet Ayano, Mikiyas Tulu, Kibrom Haile, Dawit Assefa, Yodit Habtamu, Gebresilassie Araya, Zegeye Yohannis
Background: People with severe mental disorders (SMDs) are associated with increased risk of infectious disease including human immunodeficiency virus infection (HIV) and hepatitis viruses, such as hepatitis B virus (HBV), hepatitis C virus (HCV), and other types of hepatitis viruses because of high-risk behaviors compared to the general population. The prevalence of HIV in people with SMDs is higher in females than in males. Unlike HIV, the prevalence of HBV and HCV is higher in males than in females...
2018: Annals of General Psychiatry
https://www.readbyqxmd.com/read/29751763/harm-reduction-and-viral-hepatitis-c-in-european-prisons-a-cross-sectional-survey-of-25-countries
#15
Rob Bielen, Samya R Stumo, Rachel Halford, Klára Werling, Tatjana Reic, Heino Stöver, Geert Robaeys, Jeffrey V Lazarus
BACKGROUND: Current estimates suggest that 15% of all prisoners worldwide are chronically infected with the hepatitis C virus (HCV), and this number is even higher in regions with high rates of injecting drug use. Although harm reduction services such as opioid substitution therapy (OST) and needle and syringe programs (NSPs) are effective in preventing the further spread of HCV and HIV, the extent to which these are available in prisons varies significantly across countries. METHODS: The Hep-CORE study surveyed liver patient groups from 25 European countries in 2016 and mid-2017 on national policies related to harm reduction, testing/screening, and treatment for HCV in prison settings...
May 11, 2018: Harm Reduction Journal
https://www.readbyqxmd.com/read/29750893/disparities-in-initiation-of-direct-acting-antiviral-agents-for-hepatitis-c-virus-infection-in-an-insured-population
#16
Julia L Marcus, Leo B Hurley, Scott Chamberland, Jamila H Champsi, Laura C Gittleman, Daniel G Korn, Jennifer B Lai, Jennifer O Lam, Mary Pat Pauly, Charles P Quesenberry, Joanna Ready, Varun Saxena, Suk I Seo, David J Witt, Michael J Silverberg
OBJECTIVES: The cost of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection may contribute to treatment disparities. However, few data exist on factors associated with DAA initiation. METHODS: We conducted a retrospective cohort study of HCV-infected Kaiser Permanente Northern California members aged ≥18 during October 2014 to December 2016, using Poisson regression models to evaluate demographic, behavioral, and clinical factors associated with DAA initiation...
January 1, 2018: Public Health Reports
https://www.readbyqxmd.com/read/29746648/effects-of-sofosbuvir-based-hepatitis-c-treatment-on-the-pharmacokinetics-of-tenofovir-in-hiv-hcv-coinfected-individuals-receiving-tenofovir-disoproxil-fumarate
#17
Christine E MacBrayne, Kristen M Marks, Daniel S Fierer, Susanna Naggie, Raymond T Chung, Michael D Hughes, Arthur Y Kim, Marion G Peters, Diana M Brainard, Sharon M Seifert, Jose R Castillo-Mancilla, Lane R Bushman, Peter L Anderson, Jennifer J Kiser
Background: The nucleotide analogues tenofovir and sofosbuvir are considered to have low potential for drug interactions. Objectives: To determine the effect of sofosbuvir-based HCV treatment on plasma concentrations of tenofovir and cellular concentrations of tenofovir diphosphate. Methods: HIV-infected participants with acute HCV were treated for 12 weeks with sofosbuvir + ribavirin in Cohort 1 or 8 weeks with ledipasvir/sofosbuvir in Cohort 2 of AIDS Clinical Trials Group study 5327...
May 9, 2018: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29746453/access-to-syringe-services-programs-kentucky-north-carolina-and-west-virginia-2013-2017
#18
Danae Bixler, Greg Corby-Lee, Scott Proescholdbell, Tina Ramirez, Michael E Kilkenny, Matt LaRocco, Robert Childs, Michael R Brumage, Angela D Settle, Eyasu H Teshale, Alice Asher
The Appalachian region of the United States is experiencing a large increase in hepatitis C virus (HCV) infections related to injection drug use (IDU) (1). Syringe services programs (SSPs) providing sufficient access to safe injection equipment can reduce hepatitis C transmission by 56%; combined SSPs and medication-assisted treatment can reduce transmission by 74% (2). However, access to SSPs has been limited in the United States, especially in rural areas and southern and midwestern states (3). This report describes the expansion of SSPs in Kentucky, North Carolina, and West Virginia during 2013-August 1, 2017...
May 11, 2018: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/29743153/integrated-models-of-care-for-people-living-with-hepatitis-c-virus-and-a-substance-use-disorder-protocol-for-a-systematic-review
#19
Lianping Ti, Stephanie Parent, María Eugenia Socías
BACKGROUND: People living with a substance use disorder (SUD) are a key population within the hepatitis C virus (HCV) epidemic. While integrated and community-based models of care have shown positive outcomes among this population, the literature has been primarily focused on the HIV context. This paper outlines a systematic review protocol on the impact of various integrated models of care, which includes HCV and SUD services, on various treatment, and health-related outcomes among this population...
May 9, 2018: JMIR Research Protocols
https://www.readbyqxmd.com/read/29743003/high-prevalence-of-anti-hepatitis-a-igg-in-a-cohort-of-uk-hiv-negative-men-who-have-sex-with-men-implications-for-local-hepatitis-a-vaccine-policy
#20
A Bhagey, K Foster, S Ralph, A Wardropper, C White, V Wholey, S Duncan
BASHH guidelines recommend that 'the hepatitis A virus total antibody test can be offered to at-risk patients whose immune status is unknown … depending on local funding arrangements'. We sought to measure the local prevalence of anti-hepatitis A (HAV) IgG in HIV-negative men who have sex with men (MSM), to inform the utility of pre-vaccination screening. We assessed the prevalence of anti-HAV IgG in HIV-negative MSM who attended sexual health services in County Durham and Darlington, UK, from March to August 2017...
January 1, 2018: International Journal of STD & AIDS
keyword
keyword
8632
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"